Brief: Mustang Bio Announces Phase 1/2 Clinical Trial Data Of MB-106

Mustang Bio

27/10/2022 14:31

Oct 27 (Reuters) - Fortress Biotech Inc  FBIO.O :
    * MUSTANG BIO ANNOUNCES PHASE 1/2 CLINICAL TRIAL DATA OF
MB-106, A
FIRST-IN-CLASS CD20-TARGETED, AUTOLOGOUS CAR T CELL THERAPY, TO
BE PRESENTED AT 11TH INTERNATIONAL WORKSHOP FOR WALDENSTROM'S
MACROGLOBULINEMIA
    * MUSTANG BIO INC - MB-106 DEMONSTRATED 100% OVERALL
RESPONSE RATE
IN WALDENSTROM MACROGLOBULINEMIA

Source text for Eikon:  ID:nGNXM2Sjg 
Further company coverage:  FBIO.O 
 ((Reuters.Briefs@thomsonreuters.com;))